REG - Cizzle Biotechnology - Update on Development of Proprietary Antibodies

Cizzle Biotechnology HoldingsAnnouncement

05/07/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220705:nRSE2826Ra&default-theme=true

RNS Number : 2826R  Cizzle Biotechnology Holdings PLC  05 July 2022

This announcement contains inside information for the purposes of article 7 of
EU Regulation 596/2014 which forms part of domestic UK law pursuant to the
European Union (Withdrawal) Act 2018 ("UK MAR").  Upon the publication of
this announcement this inside information is now considered to be within the
public domain.

 

5 July 2022

Cizzle Biotechnology Holdings Plc

 

("Cizzle Biotechnology" or the "Company")

 

Update on the Development of Proprietary Antibodies for Early-Stage Lung
Cancer Detection Tests and Initial Indications in Detecting Other Cancers

 

Cizzle Biotechnology, the UK based diagnostics developer, is pleased to
provide an update on the Company's progress to develop antibodies for use in
its proprietary early lung cancer tests, and to announce a new project that
may extend the range of early-stage cancers that its technology can detect,
with a focus initially on breast cancer.

Highlights

·    Monoclonal antibody ("mAb") to CIZ1B now in assay optimisation

·    mAb reporter protein developed and ready for test development

·    mAb supplier agreements extended to increase use case diversity

·    Work initiated to extend use case to breast cancer

Background

Cizzle Biotechnology is developing a blood test for the early detection of
lung cancer. Its technology is based on the ability to detect a stable plasma
biomarker, a variant of CIZ1 known as CIZ1B. CIZ1 is a naturally occurring
cell nuclear protein involved in DNA replication, and the targeted CIZ1B
variant is highly correlated with early-stage lung cancer.

On 22 July 2021 the Company announced a collaboration with FairJourney
Biologics ("FJB") for the development and supply of proprietary key monoclonal
antibodies and other detector proteins that are required for developing an
enzyme-linked immunosorbent assay (sandwich "ELISA"). Since that time the
Company has significantly increased its knowledge on reagent performance and
assay formats and is pleased to announce that monoclonal reporter antibodies
have been successfully produced by FJB

The Company also recognises that it is important to develop a range of
monoclonal antibodies to detect CIZ1B and additional suppliers have been
engaged. The Company is pleased to report that it has a mouse monoclonal
antibody that specifically detects CIZ1B and that assay conditions for its use
are now being optimised. Further work is being done to isolate rabbit
monoclonals arising from the Company's initial proof of concept studies.

In parallel, new projects have been initiated to evaluate the use of CIZ1B for
the detection of other cancers, which has led to an initial focus on breast
cancer, which could widen the utility of this important cancer biomarker.

According to World Cancer Research Fund International, lung cancer is the
second most common cancer worldwide, and the most common cancer in men and the
second most common cancer in women. In total there were more than 2.2 million
new cases of lung cancer in 2020*.  Breast cancer is the most commonly
occurring cancer in women and the most common cancer overall. There were more
than 2.26 million new cases of breast cancer in women worldwide in 2020.
Survival rates vary for different cancers and it is accepted that progress in
the early detection, and so early treatment of cancer, can led to a dramatic
increase in the number of cancer survivors.

*Lung cancer statistics | World Cancer Research Fund International (wcrf.org)
(https://www.wcrf.org/cancer-trends/lung-cancer-statistics/)

Commenting, Allan Syms, Executive Chairman of Cizzle Biotechnology, said:

"It is an unfortunate fact that in the UK alone every two minutes someone is
diagnosed with cancer**. That is compounded by the fact that in its early
stage,  cancer can be asymptomatic and remain undetected until the disease
has advanced, lowering survival rates. Simple, inexpensive, blood tests for
early cancer detection can help save lives. The recent progress made in
developing these tests at Cizzle Biotechnology, not just for lung cancer, but
for a range of other cancers is a significant step forward in our ambitions to
provide the right tools to improve cancer patient outcomes."

** Cancer Statistics for the UK (cancerresearchuk.org)
(https://www.cancerresearchuk.org/health-professional/cancer-statistics-for-the-uk)

 

Enquiries:

 

 Cizzle Biotechnology Holdings plc  Via IFC Advisory
 Allan Syms (Executive Chairman)

 

 Allenby Capital Limited  +44(0) 20 33285656
 John Depasquale
 Alex Brearley

 

 Novum Securities Limited  +44(0) 20 7399 9400
 Colin Rowbury

 Jon Bellis

 

 IFC Advisory Limited  +44(0) 20 3934 6630
 Tim Metcalfe          cizzle@investor-focus.co.uk
 Florence Chandler

 

Notes to Editors:

About Cizzle Biotechnology

Cizzle Biotechnology is developing a blood test for the early detection of
lung cancer.  Cizzle Biotechnology is a spin- out from the University of
York, founded in 2006 around the work of Professor Coverley and colleagues.
Its proof-of-concept prototype test is based on the ability to detect a stable
plasma biomarker, a variant of CIZ1 known as CIZ1B.  CIZ1 is a naturally
occurring cell nuclear protein involved in DNA replication, and the targeted
CIZ1B variant is highly correlated with early-stage lung cancer.

For more information, please see https://cizzlebiotechnology.com
(https://cizzlebiotechnology.com)

You can also follow the Company through its twitter account @CizzlePlc and on
LinkedIn.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDDZGGNRDVGZZM